|
GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
|
US3758683A
(en)
|
1971-04-30 |
1973-09-11 |
R Jackson |
Insulin product
|
|
US3984696A
(en)
|
1974-12-11 |
1976-10-05 |
Medi-Ray, Inc. |
Radiation guard for X-ray table
|
|
GB1554157A
(en)
|
1975-06-13 |
1979-10-17 |
Takeda Chemical Industries Ltd |
Stable insulin preparation for intra nasal administration
|
|
US4153689A
(en)
|
1975-06-13 |
1979-05-08 |
Takeda Chemical Industries, Ltd. |
Stable insulin preparation for nasal administration
|
|
GB1527605A
(en)
|
1975-08-20 |
1978-10-04 |
Takeda Chemical Industries Ltd |
Insulin preparation for intranasal administration
|
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
|
|
US4783441A
(en)
|
1979-04-30 |
1988-11-08 |
Hoechst Aktiengesellschaft |
Aqueous protein solutions stable to denaturation
|
|
EP0018609B1
(de)
|
1979-04-30 |
1983-09-21 |
Hoechst Aktiengesellschaft |
Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
|
|
JPS55153712A
(en)
|
1979-05-18 |
1980-11-29 |
Kao Corp |
Insulin pharmaceutical preparation and its production
|
|
DE3033127A1
(de)
|
1980-09-03 |
1982-04-08 |
Hoechst Ag, 6000 Frankfurt |
Neue analoga des insulins
|
|
US4367737A
(en)
|
1981-04-06 |
1983-01-11 |
George Kozam |
Multiple barrel syringe
|
|
WO1983000288A1
(en)
|
1981-07-17 |
1983-02-03 |
Balschmidt, Per |
A stable aqueous, therapeutic insulin preparation and a process for preparing it
|
|
NL193099C
(nl)
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
|
DE3316363A1
(de)
|
1983-05-05 |
1984-11-08 |
Deutsche Babcock Anlagen Ag, 4200 Oberhausen |
Walzenrost fuer muellverbrennungsanlagen
|
|
DE3326472A1
(de)
|
1983-07-22 |
1985-02-14 |
Hoechst Ag, 6230 Frankfurt |
Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
|
|
DE3326473A1
(de)
|
1983-07-22 |
1985-01-31 |
Hoechst Ag, 6230 Frankfurt |
Pharmazeutisches mittel zur behandlung des diabetes mellitus
|
|
DE3327709A1
(de)
|
1983-07-29 |
1985-02-07 |
Hoechst Ag, 6230 Frankfurt |
Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
|
|
DE3333640A1
(de)
|
1983-09-17 |
1985-04-25 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
|
|
DE3345434A1
(de)
|
1983-12-15 |
1985-06-27 |
Siemens AG, 1000 Berlin und 8000 München |
Roentgenuntersuchungstisch
|
|
CA1244347A
(en)
|
1984-05-29 |
1988-11-08 |
Eddie H. Massey |
Stabilized insulin formulations
|
|
US4839341A
(en)
|
1984-05-29 |
1989-06-13 |
Eli Lilly And Company |
Stabilized insulin formulations
|
|
ATE50502T1
(de)
|
1984-06-09 |
1990-03-15 |
Hoechst Ag |
Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
|
|
DE3440988A1
(de)
|
1984-11-09 |
1986-07-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
|
|
DK347086D0
(da)
|
1986-07-21 |
1986-07-21 |
Novo Industri As |
Novel peptides
|
|
US5008241A
(en)
|
1985-03-12 |
1991-04-16 |
Novo Nordisk A/S |
Novel insulin peptides
|
|
DK113585D0
(da)
|
1985-03-12 |
1985-03-12 |
Novo Industri As |
Nye peptider
|
|
EP0200383A3
(en)
|
1985-04-15 |
1987-09-02 |
Eli Lilly And Company |
An improved method for administering insulin
|
|
US4689042A
(en)
|
1985-05-20 |
1987-08-25 |
Survival Technology, Inc. |
Automatic medicament ingredient mixing and injecting apparatus
|
|
DE3526995A1
(de)
|
1985-07-27 |
1987-02-05 |
Hoechst Ag |
Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
|
|
US4837316A
(en)
|
1985-08-29 |
1989-06-06 |
Fujirebio Kabushiki Kaisha |
Alkylamide derivatives with H2 -receptor antagonistic and cytoprotective action
|
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
|
US4960702A
(en)
|
1985-09-06 |
1990-10-02 |
Codon |
Methods for recovery of tissue plasminogen activator
|
|
US5496924A
(en)
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
|
DE3636903A1
(de)
|
1985-12-21 |
1987-07-02 |
Hoechst Ag |
Fusionsproteine mit eukaryotischem ballastanteil
|
|
DE3541856A1
(de)
|
1985-11-27 |
1987-06-04 |
Hoechst Ag |
Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
|
|
CA1275922C
(en)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Treatment of cancer
|
|
DE3544295A1
(de)
|
1985-12-14 |
1987-06-19 |
Bayer Ag |
Thermoplastische formmassen mit hoher kriechstromfestigkeit
|
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
PH23446A
(en)
|
1986-10-20 |
1989-08-07 |
Novo Industri As |
Peptide preparations
|
|
AU612141B2
(en)
|
1987-02-25 |
1991-07-04 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
US5034415A
(en)
|
1987-08-07 |
1991-07-23 |
Century Laboratories, Inc. |
Treatment of diabetes mellitus
|
|
DE3726655A1
(de)
|
1987-08-11 |
1989-02-23 |
Hoechst Ag |
Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
|
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
|
US6875589B1
(en)
|
1988-06-23 |
2005-04-05 |
Hoechst Aktiengesellschaft |
Mini-proinsulin, its preparation and use
|
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
|
US5225323A
(en)
|
1988-11-21 |
1993-07-06 |
Baylor College Of Medicine |
Human high-affinity neurotransmitter uptake system
|
|
AU641631B2
(en)
|
1988-12-23 |
1993-09-30 |
Novo Nordisk A/S |
Human insulin analogues
|
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
US5514646A
(en)
|
1989-02-09 |
1996-05-07 |
Chance; Ronald E. |
Insulin analogs modified at position 29 of the B chain
|
|
PT93057B
(pt)
|
1989-02-09 |
1995-12-29 |
Lilly Co Eli |
Processo para a preparacao de analogos da insulina
|
|
DK134189D0
(da)
|
1989-03-20 |
1989-03-20 |
Nordisk Gentofte |
Insulinforbindelser
|
|
AU5741590A
(en)
|
1989-05-04 |
1990-11-29 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
|
US5006718A
(en)
|
1989-07-21 |
1991-04-09 |
Lenhart Mark J |
X-ray shield for X-ray examination table
|
|
IL95495A
(en)
|
1989-08-29 |
1996-10-16 |
Hoechst Ag |
Fusion proteins their preparation and use
|
|
US5358857A
(en)
|
1989-08-29 |
1994-10-25 |
The General Hospital Corp. |
Method of preparing fusion proteins
|
|
US5227293A
(en)
|
1989-08-29 |
1993-07-13 |
The General Hospital Corporation |
Fusion proteins, their preparation and use
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
|
ATE164080T1
(de)
|
1990-05-10 |
1998-04-15 |
Bechgaard Int Res |
Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
|
|
US5397771A
(en)
|
1990-05-10 |
1995-03-14 |
Bechgaard International Research And Development A/S |
Pharmaceutical preparation
|
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
|
DK10191D0
(da)
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
|
US5272135A
(en)
*
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
|
CA2038597A1
(en)
|
1991-03-19 |
1992-09-20 |
Jose P. Garzaran |
A method and a pharmaceutical preparation for treating pain
|
|
US6468959B1
(en)
|
1991-12-05 |
2002-10-22 |
Alfatec-Pharm Gmbh |
Peroral dosage form for peptide containing medicaments, in particular insulin
|
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
|
CH682806A5
(de)
|
1992-02-21 |
1993-11-30 |
Medimpex Ets |
Injektionsgerät.
|
|
CH682805A5
(de)
|
1992-02-24 |
1993-11-30 |
Medimpex Ets |
Anzeigeeinrichtung für ein Injektionsgerät.
|
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
|
US5253785A
(en)
|
1992-04-02 |
1993-10-19 |
Habley Medical Technology Corp. |
Variable proportion dispenser
|
|
ES2097426T3
(es)
|
1992-12-02 |
1997-04-01 |
Hoechst Ag |
Procedimiento para la obtencion de proinsulina con puentes de cistina correctamente unidos.
|
|
BR9307687A
(pt)
|
1992-12-18 |
2002-02-19 |
Lilly Co Eli |
Análogos de insulina
|
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
|
US5478323A
(en)
|
1993-04-02 |
1995-12-26 |
Eli Lilly And Company |
Manifold for injection apparatus
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
ATE176482T1
(de)
|
1993-06-21 |
1999-02-15 |
Novo Nordisk As |
Asp-b28-insulinkristalle
|
|
US5506203C1
(en)
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
|
US5534488A
(en)
|
1993-08-13 |
1996-07-09 |
Eli Lilly And Company |
Insulin formulation
|
|
WO1995013799A1
(en)
|
1993-11-19 |
1995-05-26 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of biodegradable microparticles containing a biologically active agent
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
IT1265271B1
(it)
|
1993-12-14 |
1996-10-31 |
Alcatel Italia |
Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
DE4405179A1
(de)
|
1994-02-18 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
|
|
DE4405388A1
(de)
|
1994-02-19 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
|
|
EP1462096B1
(en)
|
1994-03-07 |
2008-12-10 |
Nektar Therapeutics |
Methods and compositions for pulmonary delivery of insulin
|
|
US5474978A
(en)
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5559094A
(en)
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
|
ATE197398T1
(de)
|
1994-09-09 |
2000-11-11 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
|
|
US5879584A
(en)
|
1994-09-10 |
1999-03-09 |
The Procter & Gamble Company |
Process for manufacturing aqueous compositions comprising peracids
|
|
US5547929A
(en)
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5707641A
(en)
|
1994-10-13 |
1998-01-13 |
Pharmaderm Research & Development Ltd. |
Formulations comprising therapeutically-active proteins or polypeptides
|
|
AR002976A1
(es)
|
1995-03-31 |
1998-05-27 |
Lilly Co Eli |
Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
WO1996034882A1
(en)
|
1995-05-05 |
1996-11-07 |
Eli Lilly And Company |
Single chain insulin with high bioactivity
|
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
AU6011496A
(en)
|
1995-06-08 |
1997-01-09 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
|
WO1997001331A2
(en)
|
1995-06-27 |
1997-01-16 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
|
JPH11292787A
(ja)
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
KR100600457B1
(ko)
|
1996-06-05 |
2006-07-13 |
로셰 디아그노스틱스 게엠베하 |
엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
|
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
|
WO1997048414A1
(en)
|
1996-06-20 |
1997-12-24 |
Novo Nordisk A/S |
INSULIN PREPARATIONS CONTAINING NaCl
|
|
US5948751A
(en)
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
|
HUP9904156A3
(en)
|
1996-06-20 |
2000-07-28 |
Novo Nordisk As |
Insulin preparations containing carbohydrates
|
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
|
CA2262647C
(en)
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
US5783556A
(en)
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
|
CA2468374C
(en)
|
1996-08-30 |
2010-12-21 |
Novo-Nordisk A/S |
Glp-1 derivatives
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
DK1629849T4
(en)
|
1997-01-07 |
2017-12-04 |
Amylin Pharmaceuticals Llc |
Pharmaceutical compositions comprising exedins and agonists thereof
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
CA2279836A1
(en)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
|
US6310038B1
(en)
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
|
US6043214A
(en)
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
|
WO1998042749A1
(en)
|
1997-03-20 |
1998-10-01 |
Novo Nordisk A/S |
Zinc free insulin crystals for use in pulmonary compositions
|
|
PE79099A1
(es)
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
|
JP3919235B2
(ja)
|
1997-06-13 |
2007-05-23 |
ジェネンテク，インコーポレイテッド |
抗体製剤
|
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
|
DK1019077T4
(da)
|
1997-08-08 |
2011-03-07 |
Amylin Pharmaceuticals Inc |
Hidtil ukendte exendinagonistforbindelser
|
|
DE19735711C2
(de)
|
1997-08-18 |
2001-04-26 |
Aventis Pharma Gmbh |
Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
|
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
|
KR20010024556A
(ko)
|
1997-10-24 |
2001-03-26 |
피터 지. 스트링거 |
불용성 인슐린 조성물
|
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
|
CA2309818C
(en)
|
1997-11-12 |
2009-05-05 |
Alza Corporation |
Buffered drug formulations for transdermal electrotransport delivery
|
|
EP1066314B1
(en)
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
EP1032587B2
(en)
|
1997-11-14 |
2013-03-13 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
AU1617399A
(en)
|
1997-12-05 |
1999-06-28 |
Eli Lilly And Company |
Glp-1 formulations
|
|
US5981964A
(en)
|
1997-12-22 |
1999-11-09 |
Bruce J. McAuley |
Adjustable X-ray shield and on-line dosimetry system using same
|
|
DE69924232D1
(de)
|
1998-01-09 |
2005-04-21 |
Novo Nordisk As |
Stabilisierte insulin-zubereitungen
|
|
WO1999040788A1
(en)
|
1998-02-13 |
1999-08-19 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
|
IL137904A0
(en)
|
1998-02-23 |
2001-10-31 |
Neurocrine Biosciences Inc |
Peptide analogues of insulin and pharmaceutical compositions containing the same
|
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
EP1062229A1
(en)
|
1998-03-09 |
2000-12-27 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
AU762626B2
(en)
|
1998-06-05 |
2003-07-03 |
Nutrinia Ltd |
Insulin supplemented infant formula
|
|
DE69926007T2
(de)
|
1998-10-07 |
2005-12-29 |
Medical College Of Georgia Research Institute, Inc. |
Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
|
PL197504B1
(pl)
|
1998-10-16 |
2008-04-30 |
Novo Nordisk As |
Trwałe stężone preparaty insulinowe do podawania do płuc
|
|
PT1121145E
(pt)
|
1998-10-16 |
2002-09-30 |
Novo Nordisk As |
Preparacoes de insulina contendo mentol e destinadas a administracao via pulmonar
|
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
|
WO2000029013A1
(en)
|
1998-11-18 |
2000-05-25 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
|
EP1140145B2
(en)
|
1999-01-14 |
2019-05-15 |
Amylin Pharmaceuticals, LLC |
Novel exendin agonist formulations and methods of administration thereof
|
|
DE19908041A1
(de)
|
1999-02-24 |
2000-08-31 |
Hoecker Hartwig |
Kovalent verbrückte Insulindimere
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
|
NZ514916A
(en)
|
1999-04-30 |
2004-06-25 |
Amylin Pharmaceuticals Inc |
Exendins and exendin agonists linked to polyethylene glycol polymers
|
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
|
JP2003501404A
(ja)
|
1999-06-04 |
2003-01-14 |
デルルックス ファーマシューティカル コーポレイション |
薬剤の脱水粒子からなる製剤およびこれの調製方法
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
WO2001000223A2
(en)
|
1999-06-25 |
2001-01-04 |
Minimed Inc. |
Multiple agent diabetes therapy
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
DE19930631A1
(de)
|
1999-07-02 |
2001-01-11 |
Clemens Micheler |
Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
IL148685A0
(en)
|
1999-09-21 |
2002-09-12 |
Rtp Pharma Inc |
Surface modified particulate compositions of biologically active substances
|
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
|
PL211886B1
(pl)
|
1999-10-04 |
2012-07-31 |
Novartis Vaccines & Diagnostic |
Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
|
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
|
CA2389928C
(en)
|
1999-11-03 |
2010-03-23 |
Bristol-Myers Squibb Company |
Method for treating diabetes
|
|
ES2236010T3
(es)
|
1999-12-16 |
2005-07-16 |
Eli Lilly And Company |
Composiciones de polipeptidos con estabilidad mejorada.
|
|
EP1523993A1
(en)
|
1999-12-16 |
2005-04-20 |
Eli Lilly & Company |
Polypeptide compositions with improved stability
|
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
|
US20010012829A1
(en)
*
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
|
AU2353701A
(en)
|
2000-01-11 |
2001-07-24 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
|
AU2001220765A1
(en)
|
2000-01-24 |
2001-07-31 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
|
US6395767B2
(en)
*
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
JP3540240B2
(ja)
|
2000-03-10 |
2004-07-07 |
株式会社栗本鐵工所 |
混合・混練羽根の検査用治具
|
|
WO2001093837A2
(en)
|
2000-06-08 |
2001-12-13 |
Eli Lilly And Company |
Protein powder for pulmonary delivery
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
ATE396738T1
(de)
|
2000-09-18 |
2008-06-15 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
|
KR100508695B1
(ko)
|
2001-02-13 |
2005-08-17 |
한국과학기술연구원 |
인슐린의 경구투여용 제형과 그의 제조방법
|
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
|
DE10108211A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
|
|
DE10108100A1
(de)
|
2001-02-20 |
2002-08-29 |
Aventis Pharma Gmbh |
Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
|
|
AU2002248464A1
(en)
|
2001-02-21 |
2002-09-12 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
|
AU2002258428A1
(en)
|
2001-02-26 |
2002-09-12 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of metabolic disorders, including obesity and diabetes
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
WO2002079250A1
(en)
|
2001-04-02 |
2002-10-10 |
Novo Nordisk A/S |
Insulin precursors and a process for their preparation
|
|
CN1160122C
(zh)
|
2001-04-20 |
2004-08-04 |
清华大学 |
一种制备口服胰岛素油相制剂的方法
|
|
US20030026872A1
(en)
|
2001-05-11 |
2003-02-06 |
The Procter & Gamble Co. |
Compositions having enhanced aqueous solubility and methods of their preparation
|
|
WO2003002021A2
(en)
|
2001-06-29 |
2003-01-09 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
|
FR2827604B1
(fr)
|
2001-07-17 |
2003-09-19 |
Sanofi Synthelabo |
Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
|
|
EP2275117B1
(en)
|
2001-07-31 |
2016-10-26 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendin-4, peptide analogs and uses thereof
|
|
CN1635900A
(zh)
|
2001-08-28 |
2005-07-06 |
伊莱利利公司 |
Glp－1和基础胰岛素的预混合物
|
|
WO2003035051A2
(en)
|
2001-10-19 |
2003-05-01 |
Inhale Therapeutic Systems, Inc. |
The use of proton sequestering agents in drug formulations
|
|
WO2003035028A1
(en)
|
2001-10-19 |
2003-05-01 |
Nektar Therapeutics |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
|
CN100424179C
(zh)
|
2001-11-19 |
2008-10-08 |
诺沃挪第克公司 |
制备胰岛素化合物的方法
|
|
US20030170691A1
(en)
|
2001-12-19 |
2003-09-11 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
|
|
KR20040070237A
(ko)
|
2001-12-20 |
2004-08-06 |
일라이 릴리 앤드 캄파니 |
연장된 작용 시간을 갖는 인슐린 분자
|
|
WO2003055512A1
(en)
|
2001-12-21 |
2003-07-10 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
WO2003066084A1
(en)
|
2002-02-07 |
2003-08-14 |
Novo Nordisk A/S |
Use of glp-1 compound for treatment of critically ill patients
|
|
US20100069293A1
(en)
|
2002-02-27 |
2010-03-18 |
Pharmain Corporation |
Polymeric carrier compositions for delivery of active agents, methods of making and using the same
|
|
TWI351278B
(en)
|
2002-03-01 |
2011-11-01 |
Nisshin Pharma Inc |
Agent for preventing and treating of liver disease
|
|
WO2003094951A1
(en)
|
2002-05-07 |
2003-11-20 |
Novo Nordisk A/S |
Soluble formulations comprising insulin aspart and insulin detemir
|
|
WO2003094956A1
(en)
|
2002-05-07 |
2003-11-20 |
Novo Nordisk A/S |
Soluble formulations comprising monomeric insulin and acylated insulin
|
|
KR20050000558A
(ko)
|
2002-05-17 |
2005-01-05 |
헤마테크, 엘엘씨 |
인간 항체를 제조할 수 있는 트랜스제닉 유제동물
|
|
US7115563B2
(en)
|
2002-05-29 |
2006-10-03 |
Insignion Holding Limited |
Composition and its therapeutic use
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
CA2490564A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
|
DE10235168A1
(de)
|
2002-08-01 |
2004-02-12 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Reinigung von Preproinsulin
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
US7544657B2
(en)
*
|
2002-10-02 |
2009-06-09 |
Zealand Pharma A/S |
Stabilized Exendin-4 compounds
|
|
US20050009847A1
(en)
|
2002-11-20 |
2005-01-13 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
CN1413582A
(zh)
|
2002-11-29 |
2003-04-30 |
贵州圣济堂制药有限公司 |
盐酸二甲双胍肠溶片及其制备方法
|
|
AU2003283216A1
(en)
|
2002-12-03 |
2004-06-23 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
|
GB0309154D0
(en)
|
2003-01-14 |
2003-05-28 |
Aventis Pharma Inc |
Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
|
|
GB0304822D0
(en)
|
2003-03-03 |
2003-04-09 |
Dca Internat Ltd |
Improvements in and relating to a pen-type injector
|
|
CA2518136A1
(en)
|
2003-03-04 |
2004-09-16 |
The Technology Development Company Ltd. |
Oral insulin composition and methods of making and using thereof
|
|
EP1610812A1
(en)
|
2003-03-11 |
2006-01-04 |
Novo Nordisk A/S |
Pharmaceutical preparations comprising acid-stabilised insulin
|
|
US20040186046A1
(en)
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
|
US20060217290A1
(en)
|
2003-04-29 |
2006-09-28 |
Kohn Wayne D |
Insulin analogs having protracted time action
|
|
WO2004105781A2
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
|
AU2004268648A1
(en)
|
2003-08-29 |
2005-03-10 |
Centocor, Inc. |
Method of promoting graft survival with anti-tissue factor antibodies
|
|
EP1663295A2
(en)
|
2003-09-01 |
2006-06-07 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
WO2005023291A2
(en)
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Use of glp1-agonists in the treatment of patients with type i diabetes
|
|
JP2007537981A
(ja)
*
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
EP1684793B1
(en)
|
2003-11-13 |
2011-09-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20050201978A1
(en)
|
2003-11-17 |
2005-09-15 |
Lipton James S. |
Tumor and infectious disease therapeutic compositions
|
|
JP2007515235A
(ja)
|
2003-12-22 |
2007-06-14 |
ノボ・ノルデイスク・エー／エス |
医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
WO2005067898A2
(en)
|
2004-01-07 |
2005-07-28 |
Nektar Therapeutics |
Improved sustained release compositions for pulmonary administration of insulin
|
|
US20070027063A1
(en)
|
2004-01-12 |
2007-02-01 |
Mannkind Corporation |
Method of preserving the function of insulin-producing cells
|
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
|
US20080248999A1
(en)
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
|
AU2005231359A1
(en)
|
2004-03-31 |
2005-10-20 |
Centocor, Inc. |
Human GLP-1 mimetibodies, compositions, methods and uses
|
|
AU2005245240B2
(en)
|
2004-05-20 |
2010-04-29 |
Scimar Ltd. |
Use of drug combinations for treating insulin resistance
|
|
ATE543506T1
(de)
|
2004-06-01 |
2012-02-15 |
Ares Trading Sa |
Methode zur stabilisierung von proteinen
|
|
BRPI0512535A
(pt)
|
2004-06-24 |
2008-03-25 |
Incyte Corp |
compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
|
|
EP1906991A2
(en)
|
2004-06-28 |
2008-04-09 |
Novo Nordisk A/S |
Use of glp-1 receptor agonists and/or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i, diabetes type ii and impaired pancreatic beta-cell function
|
|
CA2569381A1
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
CN101010425B
(zh)
|
2004-08-13 |
2010-05-26 |
霍夫曼-拉罗奇有限公司 |
多肽的c-末端修饰
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
|
US20080280814A1
(en)
|
2004-09-17 |
2008-11-13 |
Novo Nordisk A/S |
Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
|
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−２組成物
|
|
CA2586771A1
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of insulinotropic peptides
|
|
EP1814581B1
(en)
|
2004-11-12 |
2016-03-16 |
Novo Nordisk A/S |
Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
|
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
|
SE0402976L
(sv)
|
2004-12-03 |
2006-06-04 |
Mederio Ag |
Medicinsk produkt
|
|
EA200701362A1
(ru)
|
2004-12-22 |
2008-08-29 |
Сентокор, Инк. |
Агонисты glp-1, композиции, способы и применения
|
|
US7879361B2
(en)
|
2005-01-04 |
2011-02-01 |
Gp Medical, Inc. |
Nanoparticles for drug delivery
|
|
EP1849024A4
(en)
|
2005-02-01 |
2015-08-26 |
Canberra Ind Inc |
METHOD FOR DETECTING A MAXIMUM ENTROPY SIGNAL
|
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
|
CN101193652B
(zh)
|
2005-04-08 |
2011-11-02 |
安米林药品公司 |
包含肠降血糖素肽和非质子极性溶剂的药物制剂
|
|
EP1888118B1
(en)
*
|
2005-05-25 |
2016-08-17 |
Novo Nordisk A/S |
Polypeptide formulations stabilized with ethylenediamine
|
|
JP5198261B2
(ja)
*
|
2005-06-06 |
2013-05-15 |
カムルス エービー |
Ｇｌｐ−１類似体製剤
|
|
ATE539743T1
(de)
|
2005-06-27 |
2012-01-15 |
Newtree Co Ltd |
Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
|
|
US20080227847A1
(en)
|
2005-07-07 |
2008-09-18 |
Aditech Pharma Ab |
Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
|
|
CA2619426C
(en)
|
2005-08-19 |
2016-06-21 |
Amylin Pharmaceuticals, Inc. |
Exendin for treating diabetes and reducing body weight
|
|
US20090181887A1
(en)
|
2005-09-08 |
2009-07-16 |
Gastrotech Pharma A/S |
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
|
MY146082A
(en)
|
2005-09-14 |
2012-06-29 |
Sanofi Aventis Deutschland |
Cleavage of precursors of insulins by a variant of trypsin
|
|
PL1928499T3
(pl)
|
2005-09-20 |
2011-11-30 |
Novartis Ag |
Zastosowanie inhibitora DPP-IV do ograniczania epizodów hipoglikemii
|
|
EP1945142B1
(en)
|
2005-09-26 |
2013-12-25 |
Medtronic, Inc. |
Prosthetic cardiac and venous valves
|
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
|
US8084420B2
(en)
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
|
US20090264732A1
(en)
|
2005-10-11 |
2009-10-22 |
Huntington Medical Research Institutes |
Imaging agents and methods of use thereof
|
|
PT1940243E
(pt)
|
2005-10-24 |
2011-10-17 |
Nestec Sa |
Formulação de fibras alimentares e método de administração
|
|
EP1954242A4
(en)
|
2005-11-30 |
2012-08-01 |
Generex Pharm Inc |
ORALLY ABSORPTED PHARMACEUTICAL FORMULATION AND METHOD OF ADMINISTRATION
|
|
US20100029558A1
(en)
|
2005-12-06 |
2010-02-04 |
Bristow Cynthia L |
Alpha1 proteinase inhibitor peptides methods and use
|
|
JP5096363B2
(ja)
|
2005-12-16 |
2012-12-12 |
ネクター セラピューティックス |
Ｇｌｐ−１のポリマ複合体
|
|
US8178495B2
(en)
|
2008-06-27 |
2012-05-15 |
Duke University |
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
|
|
CA2636469A1
(en)
|
2006-01-05 |
2007-07-19 |
University Of Utah Research Foundation |
Methods and compositions related to improving properties of pharmacological agents targeting nervous system
|
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
|
US20090324701A1
(en)
|
2006-01-20 |
2009-12-31 |
Diamedica, Inc. |
Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
|
|
US20070191271A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
|
WO2007095288A2
(en)
|
2006-02-13 |
2007-08-23 |
Nektar Therapeutics |
Methionine-containing protein or peptide compositions and methods of making and using
|
|
US7763582B2
(en)
|
2006-02-21 |
2010-07-27 |
University Of Medicine And Dentistry Of New Jersey |
Localized insulin delivery for bone healing
|
|
WO2007104786A1
(en)
|
2006-03-15 |
2007-09-20 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
WO2007113205A1
(en)
*
|
2006-04-03 |
2007-10-11 |
Novo Nordisk A/S |
Glp-1 peptide agonists
|
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
|
NZ571862A
(en)
*
|
2006-04-13 |
2011-10-28 |
Ipsen Pharma Sas |
Pharmaceutical composition comprising HGLP-1, a zinc divalent metal ion and a solvent
|
|
WO2007140619A1
(en)
|
2006-06-08 |
2007-12-13 |
Diabecore Medical Inc. |
Derivatized insulin oligomers
|
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
|
US8900555B2
(en)
|
2006-07-27 |
2014-12-02 |
Nektar Therapeutics |
Insulin derivative formulations for pulmonary delivery
|
|
CA2660835A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable propperties
|
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
|
UA100497C2
(ru)
|
2006-09-07 |
2013-01-10 |
Никомед Гмбх |
Комбинированное лечение сахарного диабета
|
|
MX2009002999A
(es)
|
2006-09-22 |
2009-04-01 |
Novo Nordisk As |
Analogos de insulina resistentes a proteasa.
|
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
WO2008145323A1
(en)
|
2007-05-31 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for interferons
|
|
ES2386166T5
(es)
|
2007-06-14 |
2016-06-21 |
Sanofi-Aventis Deutschland Gmbh |
Carpule de dos cámaras con accesorio
|
|
JP2010528792A
(ja)
|
2007-06-14 |
2010-08-26 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
二重チャンバーカルプル
|
|
DK2173407T3
(da)
|
2007-07-02 |
2020-04-27 |
Hoffmann La Roche |
Anordning til indgivelse af lægemiddel
|
|
ES2368356T3
(es)
|
2007-07-06 |
2011-11-16 |
Basf Corporation |
Composición de retención gástrica basada en un producto de reacción hidrosoluble procedente de un precursor que contiene un grupo vinilo.
|
|
EP2578677A1
(en)
|
2007-08-09 |
2013-04-10 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
ES2558930T3
(es)
|
2007-08-13 |
2016-02-09 |
Novo Nordisk A/S |
Análogos de la insulina de acción rápida
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
GB0717388D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
JP2010538982A
(ja)
|
2007-09-11 |
2010-12-16 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
単独でまたはｇｌｐ−１と組み合わせて用いる、治療剤としてのインスリンｃ−ペプチドの使用
|
|
AU2008320844B2
(en)
|
2007-11-01 |
2013-08-29 |
Merck Serono S.A. |
LH liquid formulations
|
|
CN101932601B
(zh)
|
2007-11-08 |
2016-08-03 |
诺沃-诺迪斯克有限公司 |
胰岛素衍生物
|
|
BRPI0820535B8
(pt)
|
2007-11-16 |
2021-05-25 |
Novo Nordisk As |
composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
EP2231191A2
(en)
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
|
CA2711561A1
(en)
|
2008-01-04 |
2009-07-16 |
Biodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
KR20100111683A
(ko)
|
2008-01-09 |
2010-10-15 |
사노피-아벤티스 도이칠란트 게엠베하 |
극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
|
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
RU2524423C2
(ru)
|
2008-01-09 |
2014-07-27 |
Санофи-Авентис Дойчланд Гмбх |
Новые производные инсулина с чрезвычайно замедленным профилем время/действие
|
|
EP2249869B1
(en)
*
|
2008-02-08 |
2011-09-07 |
BioGeneriX AG |
Liquid formulation of fsh
|
|
WO2009102467A2
(en)
*
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
KR101556514B1
(ko)
|
2008-02-19 |
2015-10-02 |
바이오콘 리미티드 |
효모에서 발현된 정제된 이형 인슐린을 수득하는 방법
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
EP2288918A1
(en)
|
2008-05-23 |
2011-03-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
US8574214B2
(en)
|
2008-08-30 |
2013-11-05 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge and needle system therefor
|
|
US20100069292A1
(en)
|
2008-09-02 |
2010-03-18 |
Biodel, Inc. |
Insulin with a basal release profile
|
|
EP2684570A1
(en)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
MX2011003833A
(es)
*
|
2008-10-15 |
2011-06-20 |
Intarcia Therapeutics Inc |
Particulas de farmacos altamente concentradas, formulaciones, suspensiones y uso de las mismas.
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
CA3016451A1
(en)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Combination of an insulin and a glp-1 agonist
|
|
AU2009309623B9
(en)
|
2008-10-30 |
2014-10-02 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Ｐｔｈの安定化水溶液注射剤
|
|
DK2393412T3
(en)
|
2009-02-04 |
2017-12-11 |
Sanofi Aventis Deutschland |
MEDICAL DEVICE AND PROCEDURE FOR PROVIDING Glycemic Control Information
|
|
CN117547538A
(zh)
|
2009-02-13 |
2024-02-13 |
勃林格殷格翰国际有限公司 |
包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
|
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
US20120232002A1
(en)
|
2009-07-06 |
2012-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Slow-acting insulin preparations
|
|
WO2011003820A1
(de)
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Hitze- und schüttelstabile insulinzubereitungen
|
|
DK2451437T3
(en)
|
2009-07-06 |
2017-02-13 |
Sanofi Aventis Deutschland |
Aqueous INSULIN PREPARATIONS CONTAINING METHIONIN
|
|
US8709400B2
(en)
|
2009-07-27 |
2014-04-29 |
Washington University |
Inducement of organogenetic tolerance for pancreatic xenotransplant
|
|
BR112012001988A2
(pt)
|
2009-07-31 |
2017-05-09 |
Sanofi Aventis Deutschland |
composição de insulina de ação prolongada
|
|
WO2011017554A2
(en)
|
2009-08-07 |
2011-02-10 |
Mannkind Corporation |
Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
ES2398012T5
(es)
|
2009-11-13 |
2020-02-26 |
Sanofi Aventis Deutschland |
Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
|
|
RU2537239C2
(ru)
|
2009-11-13 |
2014-12-27 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
|
|
HUE026489T2
(en)
|
2009-11-13 |
2016-06-28 |
Sanofi Aventis Deutschland |
Combination of lixisenatide and metformin to treat type 2 diabetes
|
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
KR101772372B1
(ko)
|
2009-11-13 |
2017-08-29 |
사노피-아벤티스 도이칠란트 게엠베하 |
Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
|
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
BR112012020481A2
(pt)
|
2010-02-22 |
2017-01-10 |
Univ Case Western Reserve |
método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.
|
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
|
TW201141513A
(en)
|
2010-04-14 |
2011-12-01 |
Sanofi Aventis |
Insulin-siRNA conjugates
|
|
US8637458B2
(en)
|
2010-05-12 |
2014-01-28 |
Biodel Inc. |
Insulin with a stable basal release profile
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
WO2011144674A2
(en)
|
2010-05-20 |
2011-11-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
|
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
|
US9085757B2
(en)
|
2010-06-17 |
2015-07-21 |
Regents Of The University Of Minnesota |
Production of insulin producing cells
|
|
US8532933B2
(en)
|
2010-06-18 |
2013-09-10 |
Roche Diagnostics Operations, Inc. |
Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
|
|
US20130137645A1
(en)
|
2010-07-19 |
2013-05-30 |
Mary S. Rosendahl |
Modified peptides and proteins
|
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
|
|
KR20130139297A
(ko)
|
2010-10-27 |
2013-12-20 |
노보 노르디스크 에이/에스 |
다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료
|
|
WO2012065996A1
(en)
|
2010-11-15 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
|
|
WO2012066086A1
(en)
|
2010-11-17 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
|
|
JP2013545782A
(ja)
|
2010-12-14 |
2013-12-26 |
ノヴォ ノルディスク アー／エス |
長時間作用型インスリンと組み合わせた速効型インスリン
|
|
US20130085102A1
(en)
|
2011-02-02 |
2013-04-04 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycemia in diabetes mellitus type 2 patients
|
|
EP3556774B1
(en)
|
2011-03-11 |
2024-01-03 |
Beth Israel Deaconess Medical Center Inc. |
Anti-cd40 antibodies and uses thereof
|
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
|
PL2707017T3
(pl)
|
2011-05-13 |
2016-03-31 |
Sanofi Aventis Deutschland |
Liksisenatyd i metformina do leczenia cukrzycy typu 2
|
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
|
JP2014520159A
(ja)
|
2011-06-24 |
2014-08-21 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
|
|
SI2750699T1
(sl)
|
2011-08-29 |
2015-11-30 |
Sanofi-Aventis Deutschland Gmbh |
Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
ES2562651T3
(es)
|
2011-10-04 |
2016-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
|
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
|
CN107693783A
(zh)
|
2011-10-28 |
2018-02-16 |
赛诺菲-安万特德国有限公司 |
2型糖尿病的治疗方案
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
US9522235B2
(en)
|
2012-05-22 |
2016-12-20 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
|
SI3010530T1
(sl)
|
2013-06-17 |
2019-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Formulacija z določenim razmerjem inzulin glargin/liksisenatid
|
|
AR098168A1
(es)
|
2013-10-25 |
2016-05-04 |
Sanofi Sa |
Formulación estable de insulina glulisina
|